Aethlon Medical Inc (AEMD)
NASDAQ:AEMD

Aethlon Medical (AEMD) Income Statement

385 Followers

Aethlon Medical Income Statement

Last quarter (Q3 2023), Aethlon Medical's total revenue was $―, a decrease of -100.00% from the same quarter last year. In Q3, Aethlon Medical's net income was $-2.85M. See Aethlon Medical’s key income statements, including revenue, expenses, profit, and income.
Income Statement
TTM
Mar 22Mar 21Mar 20Mar 19Mar 18
Total Revenue
$ 13.12K$ 294.17K$ 659.10K$ 650.19K$ 229.63K$ 149.63K
Cost of Revenue
------
Gross Profit
-$ 294.17K----
Operating Expense
$ 7.52M$ 10.72M$ 8.55M$ 6.58M$ 6.23M$ 4.98M
Operating Income
$ -13.21M$ -10.42M$ -7.89M$ -5.93M$ -6.00M$ -4.83M
Net Non Operating Interest Income Expense
--$ -1.58K$ -54.23K$ -220.49K$ -361.60K
Other Income Expense
$ -142.12K--$ -395.82K-$ -507.12K
Pretax Income
$ -13.35M$ -10.42M$ -7.89M$ -6.38M$ -6.22M$ -5.70M
Tax Provision
------
Earnings From Equity Interest Net Of Tax
------
Net Income Common Stockholders
$ -13.35M$ -10.42M$ -7.89M$ -6.37M$ -6.19M$ -5.68M
Basic EPS
$ -0.74-$ -0.65$ -1.87$ -5.13$ -6.90
Diluted EPS
$ -0.74-$ -0.65$ -1.87$ -5.13$ -6.90
Basic Average Shares
$ 74.57M-$ 12.09M$ 3.41M$ 1.21M$ 821.14K
Diluted Average Shares
$ 74.60M-$ 12.09M$ 3.41M$ 1.21M$ 821.14K
Dividend Per Share
------
Total Operating Income As Reported
------
Reported Normalized Basic E P S
------
Reported Normalized Diluted E P S
------
Rent Expense Supplemental
------
Total Expenses
$ 7.52M$ 10.72M$ 8.55M$ 6.58M$ 6.23M$ 4.98M
Net Income From Continuing And Discontinued Operation
$ -13.35M$ -10.42M$ -7.89M$ -6.37M$ -6.19M$ -5.68M
Normalized Income
$ -10.36M-$ -7.89M$ -5.98M$ -6.19M$ -5.17M
Interest Expense
--$ 1.58K$ 54.23K$ 220.49K$ 361.60K
EBIT
$ -13.21M$ -10.42M$ -7.89M$ -6.33M$ -6.00M$ -5.34M
EBITDA
$ -10.25M$ -10.54M$ -7.85M$ -6.30M$ -5.97M$ -5.30M
Currency in USD

Aethlon Medical Earnings and Revenue History


What's Included in PREMIUM?
Make informed decisions based on Top Analysts' activity
Know what industry insiders are buying
Get actionable alerts from top Wall Street Analysts
Find out before anyone else which stock is going to shoot up
Get powerful stock screeners & detailed portfolio analysis